Vesalius, GSK partner to develop new Parkinson’s treatments
Vesalius Therapeutics has entered into an agreement with GSK to advance the development of new therapies for Parkinson’s disease and one other undisclosed neurodegenerative condition. Under the agreement, Vesalius will be responsible for identifying new